HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

donidalorsen

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - donidalorsen: 2

Experts

1.	Alexander, Veronica J: 1 article (01/2022)
2.	Baker, Brenda F: 1 article (01/2022)
3.	Bernstein, Jonathan A: 1 article (01/2022)
4.	Bordone, Laura: 1 article (01/2022)
5.	Cohn, Danny M: 1 article (01/2022)
6.	Craig, Timothy: 1 article (01/2022)
7.	Fijen, Lauré M: 1 article (01/2022)
8.	Lumry, William R: 1 article (01/2022)
9.	MacLeod, A Robert: 1 article (01/2022)
10.	Manning, Michael E: 1 article (01/2022)

Related Diseases

1.	Angioedema 01/01/2022 - "The mean change from baseline to week 17 in the Angioedema Quality of Life Questionnaire score was -26.8 points in the donidalorsen group and -6.2 points in the placebo group (mean difference, -20.7 points; 95% CI, -32.7 to -8.7). " 01/01/2022 - "The mean monthly rate of investigator-confirmed angioedema attacks was 0.23 (95% confidence interval [CI], 0.08 to 0.39) among patients receiving donidalorsen and 2.21 (95% CI, 0.58 to 3.85) among patients receiving placebo (mean difference, -90%; 95% CI, -96 to -76; P<0.001). " 01/01/2022 - "Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial. " 11/27/2023 - "Mean plasma prekallikrein and D-dimer concentrations decreased, and Angioedema Quality of Life Questionnaire total score improved from baseline to week 105 with donidalorsen. "
2.	Hereditary Angioedemas 01/01/2022 - "In this phase 2 trial, we randomly assigned, in a 2:1 ratio, patients with hereditary angioedema with C1 inhibitor deficiency to receive four subcutaneous doses of either donidalorsen (80 mg) or placebo, with one dose administered every 4 weeks. " 01/01/2022 - "Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial. " 11/27/2023 - "A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema."

Related Drugs and Biologics

1.	Prekallikrein
2.	fibrin fragment D (D-dimer)